Breaking the LSD1/KDM1A Addiction: Therapeutic Targeting of the Epigenetic Modifier in AML

LokkenA.; Zeleznik-LeN.

首页> 外文期刊>Cancer Cell >Breaking the LSD1/KDM1A Addiction: Therapeutic Targeting of the Epigenetic Modifier in AML

【24h】

Breaking the LSD1/KDM1A Addiction: Therapeutic Targeting of the Epigenetic Modifier in AML

机译：打破LSD1 / KDM1A上瘾：AML中表观遗传修饰剂的治疗靶向

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

KDM1A/LSD1, a histone H3K4/K9 demethylase and epigenetic regulator with roles in both gene activation and repression, has increased expression in multiple cancer types. Harris et al., in this issue of Cancer Cell, and Schenk et al. show that KDM1A may be a viable therapeutic target in treating AML.

机译：KDM1A / LSD1是一种组蛋白H3K4 / K9脱甲基酶，具有在基因激活和抑制中均起作用的表观遗传调节剂，在多种癌症类型中的表达均增加。哈里斯（Harris）等人（本期《癌细胞》）和申克（Schenk）等人。表明KDM1A可能是治疗AML的可行治疗靶标。

著录项

来源
《Cancer Cell》 |2012年第4期|共3页
作者
LokkenA.; Zeleznik-LeN.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Breaking the LSD1/KDM1A Addiction: Therapeutic Targeting of the Epigenetic Modifier in AML [J] . LokkenA., Zeleznik-LeN. Cancer Cell . 2012,第4期

机译：打破LSD1 / KDM1A上瘾：AML中表观遗传修饰剂的治疗靶向
2. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response [J] . Pishas Kathleen I., Drenberg Christina D., Taslim Cenny, Molecular cancer therapeutics . 2018,第9期

机译：用SP-2509对母猪肉瘤进行KDM1A / LSD1的治疗靶向与内质网应激反应进行
3. Cutting edge bioinformatics accelerate target safety assessment of epigenetic modifiers as new therapeutic targets in cancer [J] . Potkrajac Dragana Mitic, Krsmanovic Tamara, Jankovic Katica, Toxicology Letters: An International Journal Providing a Forum for Original and Pertinent Contributions in Toxicology Research . 2017,第S1期

机译：切削刃生物信息学加速表观遗传调节剂的目标安全评估，作为癌症的新治疗靶标
4. Drug Discovery Targeting PRC2 to Alter Epigenetics for Therapeutics of Triple Negative Breast Cancer [C] . Duxin Sun International Forum on Leading Edge Technologies on Crystallization Engineering and Pharmaceutics Development;Tianjin University;Tianjin Medical University . -1

机译：药物发现靶向PRC2以改变三重阴性乳腺癌治疗的表观遗传学
5. Targeting Protein-Protein Interactions for Disruption of LSD1 (KDM1A) Complexes [D] . Schwabe, Jennifer Link. 2017

机译：靶向蛋白质-蛋白质相互作用破坏LSD1（KDM1A）复合物
6. Breaking the LSD1/KDM1A Addiction: Therapeutic Targeting of the Epigenetic Modifier in AML [O] . Alyson A. Lokken, Nancy J. Zeleznik-Le -1

机译：打破LsD1 / KDm1a成瘾：在amL的后生改性剂的治疗性靶向
7. Breaking the LSD1/KDM1A Addiction: Therapeutic Targeting of the Epigenetic Modifier in AML [O] . Lokken Alyson A., Zeleznik-Le Nancy J. 2012

机译：打破LSD1 / KDM1A上瘾：AML中表观遗传修饰子的治疗目标
8. Targeting LSD1 Epigenetic Signature in Castration-Recurrent Prostate Cancer. [R] . Battaglia, S. 2014

机译：针对去势 - 复发性前列腺癌中LsD1表观遗传特征的靶向性。

Breaking the LSD1/KDM1A Addiction: Therapeutic Targeting of the Epigenetic Modifier in AML

摘要

著录项

相似文献

相关主题

期刊订阅